This site needs JavaScript to work properly. Please enable it to take advantage of the complete set of features!

Skip to main page content

Add to Collections

Your saved search

Name of saved search:

Search terms:

Test search terms

Would you like email updates of new search results?

Yes
No

Email: (change)

Frequency:

Which day?

Which day?

Report format:

Send at most:

Send even when there aren't any new results

Optional text in email:

Your RSS Feed

Comment

. 2012 Jan 5;366(1):92; author reply 92-3.

doi: 10.1056/NEJMc1112501.

Hepatocellular carcinoma

Emmanuel A Tsochatzis, Tim Meyer, Andrew K Burroughs

PMID: 22216857
DOI: 10.1056/NEJMc1112501

Comment

Hepatocellular carcinoma

Emmanuel A Tsochatzis et al. N Engl J Med. 2012.

. 2012 Jan 5;366(1):92; author reply 92-3.

doi: 10.1056/NEJMc1112501.

Authors

Emmanuel A Tsochatzis, Tim Meyer, Andrew K Burroughs

PMID: 22216857
DOI: 10.1056/NEJMc1112501

No abstract available

PubMed Disclaimer

Comment on

Hepatocellular carcinoma.
El-Serag HB. El-Serag HB. N Engl J Med. 2011 Sep 22;365(12):1118-27. doi: 10.1056/NEJMra1001683. N Engl J Med. 2011. PMID: 21992124 Review. No abstract available.

Similar articles

Hepatocellular carcinoma.
Yeh JJ, Uemura M. Yeh JJ, et al. N Engl J Med. 2012 Jan 5;366(1):92; author reply 92-3. doi: 10.1056/NEJMc1112501. N Engl J Med. 2012. PMID: 22216856 No abstract available.
Commentary: predicting survival in hepatocellular carcinoma patients.
Wong GL, Wong VW. Wong GL, et al. Aliment Pharmacol Ther. 2012 Oct;36(7):680; discussion 681. doi: 10.1111/apt.12017. Aliment Pharmacol Ther. 2012. PMID: 22966793 No abstract available.
Management of hepatocellular carcinoma.
Hobbs KE, Dusheiko GM. Hobbs KE, et al. J Hepatol. 1992 Jul;15(3):281-3. doi: 10.1016/0168-8278(92)90056-u. J Hepatol. 1992. PMID: 1332996 Review. No abstract available.
Advances in the management of hepatocellular carcinoma.
El-Serag HB. El-Serag HB. Clin Adv Hematol Oncol. 2017 Aug;15 Suppl 9(8):2-6. Clin Adv Hematol Oncol. 2017. PMID: 29036036 No abstract available.
Locoregional therapy for patients with hepatocellular carcinoma.
Geschwind JF. Geschwind JF. Clin Adv Hematol Oncol. 2015 Oct;13(10):660-2. Clin Adv Hematol Oncol. 2015. PMID: 27058570 Review. No abstract available.

See all similar articles

Cited by

MiR-491 attenuates cancer stem cells-like properties of hepatocellular carcinoma by inhibition of GIT-1/NF-κB-mediated EMT.
Yang X, Ye J, Yan H, Tang Z, Shen J, Zhang J, Yang L. Yang X, et al. Tumour Biol. 2016 Jan;37(1):201-9. doi: 10.1007/s13277-015-3687-5. Epub 2015 Jul 19. Tumour Biol. 2016. PMID: 26188902
ART and science in using transarterial chemoembolization for retreating patients with hepatocellular carcinoma.
Fatourou EM, Tsochatzis EA. Fatourou EM, et al. Hepatobiliary Surg Nutr. 2014 Dec;3(6):415-8. doi: 10.3978/j.issn.2304-3881.2014.07.01. Hepatobiliary Surg Nutr. 2014. PMID: 25568865 Free PMC article.
Safety and Efficacy of Physical Thermal Ablation Combined Sorafenib for Hepatocellular Carcinoma: A Meta-analysis.
Jin M, Yu Q, Liu Y, Xu W, Fu X, Ji B. Jin M, et al. J Clin Transl Hepatol. 2021 Apr 28;9(2):149-159. doi: 10.14218/JCTH.2020.00125. Epub 2021 Mar 8. J Clin Transl Hepatol. 2021. PMID: 34007796 Free PMC article.
Overexpression of SYF2 correlates with enhanced cell growth and poor prognosis in human hepatocellular carcinoma.
Zhang S, Shi W, Chen Y, Xu Z, Zhu J, Zhang T, Huang W, Ni R, Lu C, Zhang X. Zhang S, et al. Mol Cell Biochem. 2015 Dec;410(1-2):1-9. doi: 10.1007/s11010-015-2533-9. Epub 2015 Aug 11. Mol Cell Biochem. 2015. PMID: 26260052
Epigallocatechin Gallate Induces Hepatic Stellate Cell Senescence and Attenuates Development of Hepatocellular Carcinoma.
Sojoodi M, Wei L, Erstad DJ, Yamada S, Fujii T, Hirschfield H, Kim RS, Lauwers GY, Lanuti M, Hoshida Y, Tanabe KK, Fuchs BC. Sojoodi M, et al. Cancer Prev Res (Phila). 2020 Jun;13(6):497-508. doi: 10.1158/1940-6207.CAPR-19-0383. Epub 2020 Apr 6. Cancer Prev Res (Phila). 2020. PMID: 32253266 Free PMC article.

See all "Cited by" articles

Publication types

Actions
Actions

MeSH terms

Actions
Actions
Actions
Actions
Actions

LinkOut - more resources

Full Text Sources
- Atypon
- Ovid Technologies, Inc.
Medical
- ClinicalTrials.gov
- MedlinePlus Health Information